Who
Ronald Harold Wilfred Cooper
Director
Company insider
Files Form 4 as: Director, C4 Therapeutics; Director, Generation Bio Co; CEO & President, enGene Therapeutics; President and CEO, Albireo Pharma; Director, Genocea Biosciences.
In numbers
- Trades disclosed
- 68
- Buys
- 3
- Sells
- 6
- Bought
- $108K
- Sold
- $227K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 7 Jun 2016
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio CoBiotechnology | SEC FORM 4 Code U | —950 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Co | SEC FORM 4 Code U | —950 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —801,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —801,000 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Generation Bio Cooption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 29 Jan 2025filed 31 Jan 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —850,000 at $0.00 | filing |
| 27 Sep 2024filed 1 Oct 2024 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Bought | $57K10,000 at $5.70 | filing |
News
No headline names them, or the companies they trade most, lately.